ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Tuesday

ADC Therapeutics (NYSE:ADCT) is expected to release its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect ADC Therapeutics to post earnings of ($0.32) per share and revenue of $22.2920 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 8:30 AM ET.

ADC Therapeutics Price Performance

Shares of ADCT stock opened at $4.12 on Friday. The company has a market capitalization of $509.77 million, a PE ratio of -2.84 and a beta of 1.92. The firm’s 50-day moving average is $3.85 and its two-hundred day moving average is $3.85. ADC Therapeutics has a 12 month low of $1.05 and a 12 month high of $4.80.

Wall Street Analyst Weigh In

ADCT has been the topic of a number of recent analyst reports. Guggenheim reiterated a “buy” rating and issued a $10.00 price objective on shares of ADC Therapeutics in a report on Wednesday, November 12th. Royal Bank Of Canada restated an “outperform” rating and issued a $5.00 target price on shares of ADC Therapeutics in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of ADC Therapeutics in a report on Wednesday, January 21st. Finally, Wall Street Zen raised ADC Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, ADC Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $7.33.

Hedge Funds Weigh In On ADC Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ADCT. Russell Investments Group Ltd. grew its position in ADC Therapeutics by 31.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 32,502 shares of the company’s stock valued at $130,000 after acquiring an additional 7,701 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of ADC Therapeutics by 25.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,750 shares of the company’s stock valued at $166,000 after purchasing an additional 9,537 shares during the period. ExodusPoint Capital Management LP grew its holdings in shares of ADC Therapeutics by 23.6% in the fourth quarter. ExodusPoint Capital Management LP now owns 56,783 shares of the company’s stock valued at $200,000 after purchasing an additional 10,842 shares in the last quarter. Engineers Gate Manager LP purchased a new stake in ADC Therapeutics during the 4th quarter worth approximately $43,000. Finally, MetLife Investment Management LLC increased its stake in ADC Therapeutics by 65.3% during the 4th quarter. MetLife Investment Management LLC now owns 49,682 shares of the company’s stock worth $175,000 after buying an additional 19,633 shares during the period. 41.10% of the stock is currently owned by hedge funds and other institutional investors.

ADC Therapeutics Company Profile

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.